Products Press Releases Partnering Careers Contact

Featured Post

SLENYTO® (melatonin extended-release tablets) is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS).

August 11, 2026

April 8, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

March 11, 2025

ACCRUFeR® (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anemia.

August 29, 2024

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD

August 27, 2024

Kye Pharmaceuticals announces approval in Canada for ACCRUFeR® (ferric maltol) for the treatment of iron deficiency anemia in adult patients

July 24, 2024

Kye Pharmaceuticals Secures Exclusive License, Supply and Commercialization Agreement with Catalyst Pharmaceuticals for AGAMREE®, a novel treatment for Duchenne muscular dystrophy, in Canada

July 2, 2024

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Chewable Tablets for the Treatment of Children With ADHD